[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hla-class-i-histocompatibility-antigen-a-0201-alpha-chain":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",28,26,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,176],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06743126","SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",[12],"Phase 3","RECRUITING","2026-08-26T02:16:03.788292Z","2026-07-05T05:32:16.693529Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06414590","Neoadjuvant Tebentafusp for Uveal Melanoma",[20],"Phase 2","2026-08-26T02:17:43.321968Z","2026-06-16T05:54:07.916679Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07566585","Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation",[27],"Phase 1","2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.731143Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06626516","Tebentafusp-tebn With LDT in Metastatic UM",[34],"Phase 1\u002FPhase 2","2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.333515Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT06917885","CUE-102 in Recurrent Glioblastoma",[27],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:28.730650Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06070012","Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma",[20],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.678056Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06627244","Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",[20],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.511438Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05338658","Study of PAT in Patients With Solid Tumor Cancers",[27],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.915457Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.601527Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06112314","IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",[12],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:27.290016Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05549297","Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)",[12],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.069198Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06946225","ACTengine® IMA203 Combined With mRNA-4203",[27],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:26.949927Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[20],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.932385Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06660420","Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and\u002For Refractory Melanoma (PRAMETIME-Mel)",[27],"2026-08-26T02:19:24.527214Z","2026-05-05T02:35:31.867443Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06402201","First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors",[27],"2026-08-26T02:17:30.145302Z","2026-04-29T02:57:57.159591Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07276386","Phase 2 Combination of Melphalan\u002FHDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma",[20],"2026-08-26T02:16:12.203827Z","2026-04-29T02:57:57.149508Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06942442","A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma",[20],"2026-08-26T02:18:06.247899Z","2026-04-29T02:57:57.069911Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06704152","BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",[34],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.733634Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06383572","Phase I\u002FII Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Myeloid Malignancies",[34],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:29.502354Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors",[34],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.324355Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06994676","A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias",[27],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.517921Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05483491","KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",[27],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.806172Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[27],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.769481Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06778863","A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",[27],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:26.672516Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07702578","A Phase 1-3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)",[12],"2026-08-26T02:18:04.640417Z","2026-07-19T19:36:05.086207Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06940739","A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel",[34],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.628635Z",{"nct_id":170,"title":171,"phases":172,"status":173,"updated_at":174,"content_modified":175},"NCT07389239","A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.",[34],"NOT_YET_RECRUITING","2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.075289Z",{"nct_id":177,"title":178,"phases":179,"status":173,"updated_at":180,"content_modified":181},"NCT06748872","EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And\u002For Synovial Sarcoma",[27],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.536530Z"]